Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Beyond Air, Inc. Common Stock

XAIR

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Last trade $1.94
Day change -$0.08 (-3.96%)
Day range $1.90 – $2.03
Volume 10,620
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.99M
Price / earnings
—
Price / book
0.37×
Price / sales
0.24×
EV / sales
2.27×
EV / EBITDA
-0.81×

Profitability

Earnings per share
-$33.90
Return on assets
-92.05%
Return on equity
-626.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
4.14×
Current ratio
4.1×
Quick ratio
3.92×
Cash ratio
0.83×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.22M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XAIR, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$2.32M$1.77M$1.91M$2.19M$1.82M$1.76M$1.15M$1.07M
Cost of revenue$2.13M$1.54M$1.81M$1.89M$2.12M$1.6M$1.18M$1.29M
Gross profit$197K$225K$94K$300K-$298K$156K-$32K-$215K
Selling, general and administrative$4.59M$4.88M$4.99M$4.47M$4.91M$4.69M$3.88M$7.73M
Research and development$1.58M$1.96M$2.28M$2.43M$2.45M$3.09M$3.26M$3.01M
Total operating expenses$6.17M$6.84M$7.26M$6.9M$7.36M$7.77M$7.14M$10.74M
Operating income-$5.98M-$6.61M-$7.17M-$6.6M-$7.66M-$7.62M-$7.17M-$10.95M
Interest expense-$1.5M-$1.49M-$1.24M-$1.09M-$639K-$548K-$580K-$549K
Income before taxes-$8.18M-$8.15M-$10.37M-$7.63M-$8.26M-$8.08M-$8.06M-$13.33M
Income taxes$0$0$0$0$0$0$0$0
Net income-$8.18M-$8.15M-$10.37M-$7.63M-$8.26M-$8.08M-$8.06M-$13.33M
Net income attributable to common shareholders-$7.82M-$7.94M-$10.28M-$7.34M-$7.94M-$7.69M-$8.03M-$13.03M
EBITDA-$5.13M-$5.82M-$6.34M-$5.8M-$6.84M-$6.81M-$6.33M-$10.16M
Basic earnings per share-$3.76-$11.00-$15.56-$17.00-$24.98-$30.67-$35.81-$59.20
Diluted earnings per share-$3.76-$11.00-$15.56-$17.00-$24.98-$30.67-$35.81-$59.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Beyond Air has agreed to sell its 58% stake in NeuroNOS to UNIVO Pharmaceutical Industries in exchange for 19.99% equity stake in UNIVO and up to $32.5 million in development and commercial milestone payments. The transaction allows Beyond Air to focus on its core LungFit business while NeuroNOS gains dedicated resources to advance its neurological disorder and brain cancer treatment pipeline.

The Motley Fool

Beyond Air (XAIR) Q4 2026 Earnings Call Transcript

Beyond Air reported fiscal 2026 revenue of $7.7 million, up 107% year-over-year, with a 90% customer renewal rate. The company is focusing resources on its LungFit PH nitric oxide delivery system and expects FDA approval of its second-generation device in late 2026. Management projects 2027 revenue of $16-18 million (110%+ growth) assuming Gen 2 launch, with expanded market access through three major GPO agreements covering ~7,000 hospitals. The company reduced net cash burn by 56% and achieved gross profit of $300,000 in fiscal 2026.

GlobeNewswire Inc.

Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting

Beyond Air (XAIR) is urging stockholders to vote in favor of a reverse stock split (1-for-2 to 1-for-20 ratio) at a June 18, 2026 special meeting to maintain its Nasdaq listing. The company received a delisting notice from Nasdaq on April 7, 2026, due to its stock price falling below the $1.00 minimum bid requirement for 30 consecutive business days. The reverse split is necessary to increase the per-share price and avoid delisting, which would impact capital access and investor eligibility.

GlobeNewswire Inc.

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Cancer, Ltd. presented updated Phase 1 trial data showing six of ten heavily pre-treated cancer patients remain alive 22-40 months after a single UNO (ultra-high concentration nitric oxide) injection. Two triple negative breast cancer patients showed no evidence of disease. The company also received a U.S. patent allowance for its proprietary gas delivery technology. Safety profile was generally favorable with mostly Grade 1-2 adverse events.

GlobeNewswire Inc.

Beyond Air to Participate in the 38th Annual Roth Conference in March

Beyond Air, Inc. (NASDAQ: XAIR) announced that Chairman & CEO Steve Lisi will participate in the 38th Annual Roth Conference on March 23, 2026, in Laguna Niguel, CA. The company will present via fireside chat and offer one-on-one meetings with investors. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 13, 20261-for-20reverse split
Jul 14, 20251-for-20reverse split